肝癌组织乙酰肝素酶的表达及其与微血管密度的关系

doi:10.3969/j.issn.1672-5069.2015.06.019

Abstract

Abstract: Objective To explore the expression of heparanase（Hpa） in liver cancer tissues, and its relationship with the microvascular density（MVD）. Methods The Hpa mRNA levels in tumor, close-adjacent cancerous （group A） and peri-cancerous liver tissues （group B） from 47 patients with primary liver cancer were detected by RT-PCR. The expression of Hpa protein and CD34 in liver and cancer tissues were detected by immunohistochemistry. The correlation of Hpa mRNA to MVD in tissues with different clinical and pathological characteristics were analyzed. Results There were significant differences between Hpa levels in tumor tissues with different differentiation and clinical stages,with or without metastasis and recurrence,high or low AFP levels,with or without portal vein tumor emboli,and large or small tumor sizes （P<0.05）;The Hpa mRNA levels （0.793±0.184） and the MVD（34.5±12.2） in liver cancerous tissues were significantly higher than those in group A and group B （P<0.05）,while the Hpa mRNA levels and MVD in group A were significantly higher than those in group B [（0.577±0.145） vs. （0.384±0.117）,and （22.2±10.7） vs. （14.7±7.4）,respectively,P<0.05];The Hpa mRNA level in each group was positively correlated with MVD（r=0.627,P<0.05）. Conclusion Hpa plays an important role in the growth,invasion and angiogenesis of hepatocellular carcinoma.

Key words: Hepatocellular carcinoma, Heparanase, Microvascular density

Yang Qirong， Zhang Ping'an.. Expression of heparanase in liver cancer tissues and its relationship with microvascular density[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(6): 643-646.

References

[1] 杨浩,杨连粤. 肝癌术后复发转移相关因素研究进展. 中国实用外科杂志,2012,32（10）:868-870.
[2] 邱谢武,于聪慧. 肝癌干细胞与肝癌复发转移的研究进展.世界华人消化杂志,2011,19（17）:1802-1807.
[3] Nadir Y,Brenner B. Heparanase multiple effects in cancer.Thrombosis Res,2014,133（Suppl 2）:S90-S94.
[4] 石志良,秦锡虎,朱峰,等. 肝细胞肝癌中乙酰肝素酶mRNA的表达及其意义. 实用临床医学,2006,7（8）:1-3.
[5] Seifert C,Wittig S,Arndt C,et al. Heparanase polymorphisms: influence on incidence of hepatic sinusoidal obstruction syndrome in children undergoing allogeneic hematopoietic stem cell transplantation. J Cancer Res Clin,2015,141（5）:877-885.
[6] Roucourt B,Meeussen S,Bao J,et al. Heparanase activates the syndecan-syntenin-ALIX exosome pathway.Cell Res,2015,25（4）:412-428.
[7] Zeng C,Chen L,Yang Z,et al. The close correlation between heparanase and COX-2 expression in lymphangiogenesis of cervical cancer. Med Oncol,2014,31（12）:314.
[8] Gawthorpe S,Brown JE,Arif M,et al. Heparanaseand COX-2 expression as predictors of lymph node metastasis in large,high-grade breast tumors. Anticancer Res,2014,34（6）:2797-2800.
[9] Pisano C,Vlodavsky I,Ilan N,et al. The potential of heparanase as a therapeutic target in cancer. Biochem Pharmacol,2014,89（1）:12-19.
[10] Masola V,Secchi MF,Gambaro G,et al. Heparanase as a target in cancer therapy. Curr Cancer Drug Targets,2014,14（3）:286-293.
[11] Novick D,Barak S,Ilan N,et al. Heparanase interacts with resistin and augments its activity.PloS one,2014,9（1）:e85944.
[12] Meirovitz A,Goldberg R,Binder A,et al. Heparanase in inflammation and inflammation-associated cancer. The FEBS J,2013,280（10）:2307-2319.
[13] Cohen E,Doweck I,Naroditsky I,et al. Heparanase is overexpressed in lung cancer and correlates inversely with patient survival. Cancer,2008,113（5）:1004-1012.
[14] 田志宏,王顺祥,张凤瑞. 乙酰肝素酶在原发性肝细胞肝癌中的表达及临床意义. 河北医科大学学报,2007,28（3）:172-174.
[15] 崔京远,马红,马文慧,等. 结肠癌组织中Cyr61和HPA-1的表达水平及其在侵袭转移中的作用.中国现代普通外科进展,2012,15（6）:439-443.
[16] 刘华敏,李玉军,梁军,等. 胰腺癌组织乙酰肝素酶表达及其与肿瘤血管形成及预后关系的研究.中华肿瘤防治杂志,2008,15（2）:134-137.
[17] 朱陈辉,胡卫列,夏照明,等. 环氧合酶-2和乙酰肝素酶-1在肾上腺皮质肿瘤中的表达及临床意义.实用医学杂志,2012,28（9）: 1465-1468.
[18] 乔建霞,师水生. Delta like蛋白及乙酰肝素酶在食管鳞状细胞癌中的表达及其与微血管密度关系的研究.中国药物与临床,2012,12（8）:1020-1023.
[19] 王贺,孙风波,邢智远,等. 原发性肝癌组织中LASP-1 mRNA和HPA-1 mRNA表达水平及其临床意义.中国临床研究,2014,27（6）:641-643.
[20] 肖影群,邓茜,梁青,等. 早期肝细胞肝癌组织中乙酰肝素酶、b-FGF、CD34的表达与微血管密度的关系及其病理和临床意义.南昌大学学报（医学版）,2010,50（4）:4-9.
[21] 温德才,高若辉,李秀军. 胆囊癌组织乙酰肝素酶的表达与胆囊癌临床病理参数及微血管密度的关系.江苏医药,2011,37（19）:2302-2304.

Expression of heparanase in liver cancer tissues and its relationship with microvascular density

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[2]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[3]	Zhu Jun, Ding Ying, Wang Shiqing, et al. Peripheral blood Th22 cells and plasma interleukin-22 level changes in patients with hepatocellular carcinoma after hepatectomy and administration of ulinastatin [J]. Journal of Practical Hepatology, 2019, 22(5): 720-723.
[4]	Wang Gang, Zhao Hongbo, Zhu Yaling, et al. Cancerous XPO5 gene level in patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Practical Hepatology, 2019, 22(5): 724-727.
[5]	Qiao Zhizhong. Value of contrast-enhanced ultrasonography in differential diagnosis of patients with focal nodular hyperplasia and hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 421-424.
[6]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.
[7]	Wang Huming, Fan Dongsheng, Xu Jie, Liu Xianfegn, Zhou Ning, Li Min, Bao Nana. Cancerous miRNA-30c levels affecting the survival of patients with hepatocellular carcinoma after hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 248-251.
[8]	Xing Diankui, Cheng Jing. Clinical value of ¹⁸F-FDG PET/CT scan in patients with hepatocellular carcinoma and hepatic microvascular invasion [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 252-254.
[9]	Wang Xiuqing, Ma Yanjun, Zhan Jinli. Efficacy of transcatheter arterial chemoembolization and ultrasound-guided microwave ablation in the treatment of patients with hepatocellular carcinoma at special sites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 260-263.
[10]	Zhang Xiaozhou, Shuai Ling, Wang Qingda, Yang Nan. Changes of serum miR-335 levels in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 268-271.
[11]	Wang Zhaoxia, Guan Ke, Fu Sanxian, Wang Huijie. Early administration of enteral nutrition in patients with hepatocellular carcinoma undergoing hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 272-275.
[12]	Zhao Xitai, Nie Qinghe. Serum microRNA in diagnosis of patients with hepatocellular carcinoma and methodological progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 297-300.
[13]	Fan Jiangao.. Highlights of Journal of Practical Hepatology in 2018 [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 1-3.
[14]	Chen Yongqi, Chen Qian, Yuan Chunyan, et al.. Cancerous and noncancerous expression of Ep-CAM and C-Kit in patients with hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 109-112.
[15]	Ouyang Shi, Chen Xiaoping, Cheng Tao, et al.. Correlation of HLA-A,-B,-C,-DRB1,-DQB1 alleles to hepatocellular carcinoma development in patients with hepatitis B viral infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 940-946.